TY - JOUR
T1 - Plasmablast, memory B cell, CD4+ T cell, and circulating follicular helper T cell responses to a non-replicating modified vaccinia ankara vaccine
AU - Anderson, Evan J.
AU - Lai, Lilin
AU - Wrammert, Jens
AU - Kabbani, Sarah
AU - Xu, Yongxian
AU - Priyamvada, Lalita
AU - Hill, Heather
AU - Goll, Johannes B.
AU - Jensen, Travis L.
AU - Kao, Carol
AU - Yildirim, Inci
AU - Rouphael, Nadine
AU - Jackson, Lisa
AU - Mulligan, Mark J.
N1 - Funding Information:
This work was funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health under Contract Numbers HHSN272200800005C and HHSN272201300018I to Emory and HHSN272200800004C to Group Health. Support was provided to SK by the Emory Vaccinology Training Program 5T32AI074492. Additional support was provided by the Georgia Research Alliance (GRA). We thank the teams of Emory Children’s Center and Hope Clinic of the Emory Vaccine Center for their efforts on behalf of this study, particularly Kathy Stephens, Brooke Hartwell, Andres Camacho- Gonzalez, Paul Spearman, Andi Shane, Anita McElroy, Melanie Johnson, Larry Anderson, Theda Gibson, Laila Hussaini, Bethany Sederdahl, Leslie Smitley, Allison Beck, Sri Edupuganti, Colleen Kelley, Dawn Battle, Mary Bower, Justin Colwell, Ellen DeStefano, Briyana Domjahn, Eileen Osinski, Pamela Turner, Dongli Wang, JoAnn Sadowski, and Yongxian Xu. From Emmes, we thank Jeanine May, Dan Sinnett, and Lisa Davis for their efforts on this study. We also thank DMID and particularly Robert Johnson, Suzanne Murray, and Marianne Baker for their support of this study. The content is solely the responsibility of the authors and does not necessarily reflect the official views of the National Institutes of Health.
Funding Information:
Funding: This work was funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health under Contract Numbers HHSN272200800005C and HHSN272201300018I to Emory and HHSN272200800004C to Group Health. Support was provided to SK by the Emory Vaccinology Training Program 5T32AI074492. Additional support was provided by the Georgia Research Alliance (GRA).
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/3
Y1 - 2020/3
N2 - Background: Vaccinia is known to induce antibody and cellular responses. Plasmablast, circulating follicular helper T (cTFH) cells, cytokine-expressing CD4 T cells, and memory B cells were compared between subcutaneous (SC) and needle-free jet injection (JI) recipients of non-replicating modified vaccinia Ankara (MVA) vaccine. Methods: Vaccinia-naïve adults received MVA SC or by JI on Days 1 and 29. Vaccinia-specific antibodies were quantified by plaque reduction neutralization test (PRNT) and enzyme-linked immunosorbent assay. Plasmablast, cTFH, and cytokine-expressing CD4 T cells were assessed on Days 1, 8, 15, 29, 36, 43 (cTFH and CD4+ only) and 57. Memory B cells were measured on Days 1 and 57. Results: Of the 36 enrolled subjects, only 22 received both vaccinations and had evaluable specimens after the second vaccine. Plasmablasts peaked one week after each vaccine. Day 15 plasmablasts correlated with peak PRNT titers. cTFH peaked on Days 8 and 36 and correlated with Day 36 plasmablasts. CD4+ peaked at Day 29 and one-third produced ≥2 cytokines. Day 57 memory B cells ranged from 0.1% to 0.17% of IgG-secreting B cells. Conclusions: This study provides insights into the cellular responses to non-replicating MVA, currently used as a vector for a variety of novel vaccines.
AB - Background: Vaccinia is known to induce antibody and cellular responses. Plasmablast, circulating follicular helper T (cTFH) cells, cytokine-expressing CD4 T cells, and memory B cells were compared between subcutaneous (SC) and needle-free jet injection (JI) recipients of non-replicating modified vaccinia Ankara (MVA) vaccine. Methods: Vaccinia-naïve adults received MVA SC or by JI on Days 1 and 29. Vaccinia-specific antibodies were quantified by plaque reduction neutralization test (PRNT) and enzyme-linked immunosorbent assay. Plasmablast, cTFH, and cytokine-expressing CD4 T cells were assessed on Days 1, 8, 15, 29, 36, 43 (cTFH and CD4+ only) and 57. Memory B cells were measured on Days 1 and 57. Results: Of the 36 enrolled subjects, only 22 received both vaccinations and had evaluable specimens after the second vaccine. Plasmablasts peaked one week after each vaccine. Day 15 plasmablasts correlated with peak PRNT titers. cTFH peaked on Days 8 and 36 and correlated with Day 36 plasmablasts. CD4+ peaked at Day 29 and one-third produced ≥2 cytokines. Day 57 memory B cells ranged from 0.1% to 0.17% of IgG-secreting B cells. Conclusions: This study provides insights into the cellular responses to non-replicating MVA, currently used as a vector for a variety of novel vaccines.
KW - Antibody secreting cells
KW - Follicular helper T cells (TFH)
KW - MVA
KW - Plasmablasts
KW - Smallpox
KW - Vaccinia
UR - http://www.scopus.com/inward/record.url?scp=85079439100&partnerID=8YFLogxK
U2 - 10.3390/vaccines8010069
DO - 10.3390/vaccines8010069
M3 - Article
C2 - 32041104
AN - SCOPUS:85079439100
SN - 2076-393X
VL - 8
JO - Vaccines
JF - Vaccines
IS - 1
M1 - 69
ER -